{"disease":{"id":"anaplastic-large-cell-lymphoma-alk-positive","name":"anaplastic large cell lymphoma alk positive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT01979536","title":"Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06176690","title":"Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT03493451","title":"Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":77,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02561273","title":"Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT03113500","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03603847","title":"Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"The Lymphoma Academic Research Organisation","has_results":false},{"nct_id":"NCT07013565","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"New York Medical College","has_results":false},{"nct_id":"NCT03719898","title":"Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT02729961","title":"Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Washington","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}